Crucial Commission studies to shape new regulatory practices
This article was originally published in Clinica
The European Commission's agenda for the remainder of 2007 includes several studies critical to tightening up the EU's medtech regulatory act. Items under the spotlight for the next few months will include: reprocessing, counterfeiting, vigilance and the overlap with the Advanced Therapies Medicinal Products Regulation.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.